12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

BG-12 regulatory update

FDA extended the PDUFA date by 3 months for an NDA from Biogen Idec for BG-12 to treat multiple sclerosis. The delay would move a potential decision into early next year; Biogen Idec had expected a decision by year end. According to the...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >